EU and US could reach trade deal this weekend - Reuters
On Thursday, Erste Group analysts downgraded Eli Lilly stock (NYSE: NYSE:LLY) from a buy rating to hold. This decision comes amid concerns about the company’s future earnings projections. According to InvestingPro data, the pharmaceutical giant currently trades at a P/E ratio of 62, reflecting premium market valuation.
Eli Lilly, known for its robust pipeline of potentially successful drugs and high-demand products, had previously been anticipated to experience significant growth in sales and profits this year. The company has demonstrated strong performance with 36.38% revenue growth in the last twelve months. However, the company’s recent first-quarter report revealed a revised earnings per share forecast for 2025. The forecast was adjusted to a range of $20.2 to $21.7, while analyst targets range from $650 to $1,190 per share.
The downgrade reflects Erste Group’s expectation that Eli Lilly shares will likely trend sideways in the medium term. Analysts pointed to the lowered earnings forecast as a key factor influencing their decision to adjust the stock rating. For deeper insights into Eli Lilly’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.
Eli Lilly’s extensive drug pipeline and current market demand for its products remain strong, with the company maintaining a "GOOD" overall financial health score, yet the revised earnings outlook suggests a more cautious approach for investors moving forward.
In other recent news, Eli Lilly has announced positive Phase 1 results for its investigational ovarian cancer drug, LY4170156. The drug demonstrated a favorable safety profile and an objective response rate of 55% in patients with advanced ovarian cancer, as presented at the American Society of Clinical Oncology Annual Meeting. Meanwhile, Eli Lilly has also made a strategic move by agreeing to acquire SiteOne Therapeutics in a deal valued at up to $1 billion. This acquisition aims to enhance Lilly’s non-opioid pain management portfolio, focusing on SiteOne’s Nav 1.8 inhibitor, STC-004, which is in Phase 2 development.
UBS has maintained a Buy rating on Eli Lilly stock, with a price target of $1,050, reflecting confidence in the company’s growth prospects amid broader market concerns. Similarly, BMO Capital has reiterated its Outperform rating on Eli Lilly, setting a price target of $900. These developments underscore the company’s strategic focus on expanding its therapeutic offerings and maintaining investor confidence. Additionally, the use of Novo Nordisk (NYSE:NVO)’s weight-loss drug Wegovy has increased significantly among American teenagers, with prescription rates rising to 17.3 per 100,000 adolescents. This trend highlights a growing interest in medical interventions for obesity management in younger populations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.